Civica and Blue Cross Blue Shield launch new venture to lower generic prices
Five years after Martin Shkreli put a smug face to the volatile prices companies can charge even for generic drugs, payers and governments are coming up with outside-the-box solutions.
The latest fix is a new venture from the Blue Cross Blue Shield Association, 18 of its members and Civica, the generics company founded in 2018 by hospitals fed up with high prices for drugs that had long-since lost patent protection. While Civica focused on drugs that hospitals purchased, the new company will aim to lower prices on drugs that, like Shkreli’s Daraprim, are purchased by individuals.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 94,200+ biopharma pros reading Endpoints daily — and it's free.